Greenleaf Trust Has $3.07 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Greenleaf Trust reduced its position in Novo Nordisk A/S (NYSE:NVO) by 0.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 35,652 shares of the company’s stock after selling 152 shares during the period. Greenleaf Trust’s holdings in Novo Nordisk A/S were worth $3,067,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. International Assets Investment Management LLC lifted its position in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. Mediolanum International Funds Ltd acquired a new stake in Novo Nordisk A/S during the third quarter worth approximately $98,765,000. DAVENPORT & Co LLC lifted its position in Novo Nordisk A/S by 75.1% during the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after acquiring an additional 451,641 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Novo Nordisk A/S during the third quarter worth approximately $42,017,000. Finally, World Investment Advisors LLC lifted its position in Novo Nordisk A/S by 2,655.9% during the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock worth $33,388,000 after acquiring an additional 270,234 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on NVO. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $84.36 on Monday. The company’s 50 day simple moving average is $93.56 and its 200 day simple moving average is $113.03. The stock has a market capitalization of $378.56 billion, a price-to-earnings ratio of 27.30, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.